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OBJECTIVES: To report the effect of BG-12 (dimethyl fumarate) in reducing the 
number of relapses requiring intravenous (IV) steroids and multiple sclerosis 
(MS)-related hospitalizations from a pre-specified integrated analysis of DEFINE 
and CONFIRM, which was designed to estimate–more precisely–the therapeutic 
effect of BG-12 versus placebo. METHODS: Eligible patients were aged 18–55 
years with relapsing–remitting MS (McDonald criteria) and an Expanded 
Disability Status Scale score of 0–5.0. Patients who received oral BG-12 240 mg 
twice (BID) or three times daily (TID) or placebo were included and the integrated 
analysis was to be conducted only if baseline characteristics and treatment 
effects were similar between the studies. Numbers of relapses requiring IV 
steroids and MS-related hospitalizations (tertiary endpoints in DEFINE and 
CONFIRM) were assessed. RESULTS: The integrated analysis included 769, 761, 
and 771 patients who received BG-12 BID, TID, and placebo, respectively. 
Baseline characteristics and treatment effects were generally similar between 
DEFINE and CONFIRM. There were significantly fewer relapses requiring steroids 
and MS-related hospitalizations in both BG-12 groups compared with placebo. 
BG-12 reduced the annualized rate of relapses requiring IV steroids by 48% (BID; 
rate ratio, 0.52 [95% confidence interval, 0.43–0.64]) and 50% (TID; 0.50 [0.41–0.61]) 
versus placebo (both p<0.0001) and reduced the annualized rate of MS-related 
hospitalizations by 34% (BID; 0.66 [0.47–0.92]; p=0.0146) and 47% (TID; 0.53 [0.37–
0.75]; p=0.0004) at 2 years. CONCLUSIONS: BG-12 significantly reduced the 
number of relapses requiring IV steroids and MS-related hospitalizations, which 
suggests benefits with regard to patient burden and health economic savings due 
to decreased resource utilization. These findings further support the efficacy 
results of DEFINE and CONFIRM.  
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OBJECTIVES: Perampanel (PER) is the first orally active α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist approved for the 
adjunctive treatment of partial-onset seizures in patients with epilepsy aged 12 
years and older. While the regulatory approval was on the basis of 3 RCTs, which 
demonstrated the efficacy and acceptable safety of perampanel relative to 
placebo, for the purpose of funding and health technology assessment decisions 
comparisons to other similar AED are necessary.The aim is to compare the 
clinical efficacy and tolerability of PER relative to other recently approved AEDs 
(lacosamide (LCM), retigabine (RTG), and eslicarbazepine (ESL)) for the adjunctive 
treatment of partial onset seizures with or without secondarily generalization. 
METHODS: A systematic literature review was conducted to identify all RCTs of 
PER and selected AEDs. EMBASE, MEDLINE, and the Cochrane Central Register of 
Controlled Trials from 1998 to September 2011, abstracts from selected 2010 and 
2011 conferences, reference lists of included studies and unpublished study 
reports were searched. The odds-ratio for three outcomes: “>50% reduction in 
seizure frequency”, “seizure freedom” and “withdrawal due to adverse events” 
were estimated using fixed- and random-effects Bayesian NMA models. 
RESULTS: Twelve RCTs (3 PER, 3 LCM, 3 RTG and 3 ESL) met the inclusion criteria. 
In the analysis for “>50% reduction in seizure frequency”, all AEDs performed 
significantly better than placebo with odds-ratio for PER being similar to the 
other comparators. In the analysis for “seizure freedom”, all AEDs except LCM 
performed significantly better than placebo. In the analysis for “withdrawal due 
to adverse events” PER had the lowest odds-ratio compared to other AEDs. No 
significant difference was observed in any of the three outcomes between PER 
and the other AEDs when compared against each other. CONCLUSIONS: 
Compared with other licensed adjunctive AEDs, perampanel offers similar 
clinical efficacy and tolerability profile.  
 
PND13  
CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL 
FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING–REMITTING 
MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 
DEFINE AND CONFIRM STUDIES  
Bar-Or A1, Fox RJ2, Gold R3, Miller DH4, Arnold DL5, O'Gorman J6, Yang M6, Sheikh SI6, 
Viglietta V6, Dawson KT6, Hutchinson M7 
1Montreal Neurological Institute and Hospital, Montreal, QC, Canada, 2Mellen Center for Multiple 
Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA, 3St Josef Hospital, 
Bochum, Germany, 4University College London Institute of Neurology, London, UK, 5Montreal 
Neurological Institute and Hospital; and NeuroRx Research, Montreal, QC, Canada, 6Biogen Idec 
Inc., Weston, MA, USA, 7St Vincent’s University Hospital, Dublin, Ireland  
OBJECTIVES: To report efficacy of BG-12 (dimethyl fumarate) in pre-specified 
patient subgroups stratified by age, gender, treatment history, prior relapses, 
Expanded Disability Status Score (EDSS), McDonald criteria, T2 lesion volume, 
and presence/absence of gadolinium-enhancing lesions at baseline in a pre-
specified integrated analysis of DEFINE and CONFIRM. This analysis was 
designed to estimate–more precisely–the treatment effect of BG-12 versus 
placebo. METHODS: Eligible patients were aged 18–55 years with a diagnosis of 
relapsing-remitting multiple sclerosis (RRMS) (McDonald criteria) and an EDSS 
score of 0–5.0. Patients receiving BG-12 240 mg twice (BID) or three times daily 
(TID) or placebo were included in this analysis. Primary endpoints were 
proportion of patients relapsed (DEFINE) and annualized relapse rate (ARR) 
(CONFIRM) at 2 years. Secondary endpoints included number of new/enlarging 
T2 lesions and disability progression. The pre-specified integrated analysis was 
to be conducted only if baseline characteristics and treatment effects were 
consistent between the studies. RESULTS: The integrated intent-to-treat 
population comprised 2,301 patients while MRI evaluations were performed in a 
cohort of 1,046 patients. Baseline characteristics and treatment effects were 
generally similar across studies. Both BG-12 BID and TID reduced ARR versus 
placebo at 2 years by approximately 50%, risk of relapse, number of 
new/enlarging T2 lesions, and risk of disability progression at 2 years versus 
placebo across the subgroups. For example, ARR versus placebo at 2 years was 
reduced by 50% (BID; rate ratio 0.50 [95% confidence interval 0.40–0.64]) and 53% 
(TID; 0.47 [0.37–0.60]) in patients with ≤1 relapse in the year before study entry 
and 47% (BID; 0.53 [0.40–0.72]) and 41% (TID; 0.59 [0.44–0.80]) in patients with ≥2 
relapses. CONCLUSIONS: These findings further indicate consistent efficacy of 
BG-12 on both clinical and neuroradiological measures across a wide spectrum of 
RRMS patients.  
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OBJECTIVES: Migraine is a public health problem that has an impact on both the 
individual sufferer and on society. The objective of this study was to examine 
the PCS (physical component summary) and MCS (mental component summary) 
score after being treated with one of the two different recommended level A 
medications – Triptans and Anti-epileptics. METHODS: MEPS data 2003-2010 
(with panel 9-14) were downloaded from the AHRQ website. Migraine patients 
who started to receive either Triptans or Anti-epileptics in round 3 were retained 
in the cohort. Patients who received combination therapy or received the 
medication in round 1 or 2 were excluded in order to control for the baseline 
characteristics. Propensity score method was used to ensure the patients being 
compared are equal within each tertile. The predicted probability of receiving 
Triptans was calculated for all patients in the cohort by using multiple logistic 
regression to control for demographics, comorbidity and PCS/MCS in round 2. 
The probabilities were then stratified into tertiles. The outcomes – PCS and MCS 
in round 4 were compared within each tertile to examine if there were any 
differences between the two medications. RESULTS: Overall there were 120 
patients in the cohort with weighted frequency of 2,779,074 (2,049,642 for 
Triptans and 729,432 for Anti-epileptics). After the propensity score stratification, 
all the baseline information between the two treatment cohorts were equal in 
each tertile except race in tertile 2 (p=0.0124). After the outcomes comparison, 
there were no differences in round 4 PCS and MCS score between the two 
medications for all three tertiles. CONCLUSIONS: Triptans are the most 
expensive among all the migraine medications. However, the findings of our 
study demonstrated there were no differences in PCS and MCS after the 
treatment. Future studies should examine different outcomes and see if Triptans 
can improve other clinical findings.  
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OBJECTIVES: Multiple sclerosis (MS) is a common autoimmune demyelinating 
disease of the central nervous system. Early treatment of MS aids in repressing 
the most severe stage of acute axonal injury. The objective of this study was to 
characterize the proportion of MS patients who received early treatment, defined 
as an immunosuppressive treatment within 12 months following diagnosis. 
METHODS: We identified patients with an MS diagnosis who sought care in the 
US Veterans Health Administration (VHA) system from 1999-2010. The index 
date was the date of firs MS diagnosis. Patients who did not have at least 12 
months of follow-up time were excluded. Descriptive statistics were used to 
characterize prescriptions for medications commonly used to treat MS in the 12 
months following the index date. RESULTS: Our analysis cohort consisted of 
6,011 MS patients. Mean age was 53.8 (SD 13.4) years and 80.7% were male. Race 
was known in 40.8%; of which most were white (80.2%) or black (16.0%). Only 
35.3% of MS patients had a prescription for MS treatment in the 12 months 
following the index date. The most common MS treatments among MS patients 
were interferon beta 1a (13.2%), glatiramer (10.3%), amantadine (6.9%), 
prednisone (6.5%), and methylprednisolone (5.5%). Younger patients were more 
likely to have prescriptions. In a subset of 3,312 patients age <55, e.g., those who 
would be eligible for a clinical trial, 44.1% had a prescription for any 
immunosuppressive therapy used to treat MS. Interferon beta 1a (17.9%) was the 
most common treatment in this subgroup followed by glatiramer (13.6%), 
amantadine (8.9%), methylprednisolone (7.3%), and prednisone (6.8%). 
CONCLUSIONS: This descriptive analysis indicates that most patients with a 
diagnosis of MS do not receive early immunosuppressive therapy. Future 
research should identify relevant barriers to treatment and potential solutions to 
overcoming these barriers.  
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